. 2009 Apr 2;3:27–44. doi: 10.2174/1874205X00903010027

Table 5.

Selection of Treatments Investigated to Modify the Course of AD. Multifunctional Drugs can be Found in More than One Section

Action
They reduce βA production	atorvastatin^^a, bis-tacrine, cerebrolysine^, fenretinide, flurbiprofen^, GSK 188909, huperzine A^a, ibuprofen^^b, ladostigil, leuprorelin^^b, LY450139^b, memoquin, imatinib^, neuropeptide PACAP, simvastatin^*^b
They inhibit βA aggregation	AZD-103, β-sheet-brakers, colostrinin, curcumin, lipocrine, memoquin, PBT-2^a, tramiprosate
They enhance βA elimination	PAI-1 or TGB-β1 antagonists, curcumin, active immunotherapy (ACC-001, CAD-106), passive immunotherapy (bapineuzumab^b), intranasal insulin, rosiglitazone^*^b
They reduce neurofibrillary degeneration	aloisines, indirubin derivatives, hymenialdisine, anti-phospho-τ immunotherapy, lithium^, lovastatin^, memantine^, memoquin, nicotinamide^, paullones, thiadiazolidinones
They decrease excitotoxicity and oxidative stress	docosahexaenoic acid^^b, ω3 fatty acids^ + lipoic acid^, bis-tacrine, colostrinin, curcumin, dihydroepiandrosterone^, dimebon^b, tacrine-melatonin hybrids, huperzine A^a, ladostigil, lipocrine, melatonin^, memantine^, memoquin, neramexane^b, PBT-2^a, rosiglitazone^^b, vitamins E+C^

PAI = plasminogen activator inhibitor. TGB: transforming grow factor.

: Currently marketed.

In phase-II

^(a)

or phase-III

^(b)